Phase I Study of 4-Demethoxydaunorubicin by Oral Route in Patients with Advanced Cancer

Authors

  • A. Krarup- Hansen Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • E. Andersen Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • K. Elbaek Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • S. N. Rasmussen Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • M. Dalmark Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • E. Andersen Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • K. Elbaek Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark
  • S. N. Rasmussen Department of Oncology Ona, The Finsen Institute, Copenhagen, Denmark; Department of Pharmacology, The Royal Danish School of Pharmacy, DK-2100, Copenhagen, Denmark

DOI:

https://doi.org/10.3109/02841868809093581

Keywords:

Chemotherapy, 4-demethoxydaunorubicin, phase I study, plasma concentrations`

Abstract

In a phase I trial 4-demethoxydaunorubicin (4-dm DNR) was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid tumors. No fatal toxicity was observed at doses up to 25.0 mg/m2. Dose-limiting granulocytopenia and non-hematologic toxicity developed at dosages ≥22.5 mg/m2. No response to the therapy was observed. The plasma concentrations of 4-dm DNR were measured in 4 of the patients.

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Krarup- Hansen, A., Andersen, E., Elbaek, K., Rasmussen, S. N., Dalmark, M., Andersen, E., … Rasmussen, S. N. (1988). Phase I Study of 4-Demethoxydaunorubicin by Oral Route in Patients with Advanced Cancer. Acta Oncologica, 27(5), 521–525. https://doi.org/10.3109/02841868809093581

Issue

Vol. 27 No. 5 (1988): Acta Oncologica

Section

Articles